FDA told South Korea's COSMO KOREA that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
What happened
FDA reviewed the company's website, www.cosmo-korea.com, rather than conducting an inspection. FDA found the site offering injectable botulinum toxin drug products for sale to U.S. consumers, including one marketed as "Nabota 200ui" and described with claims such as "blepharospasm elimination" and "hyperhidrosis elimination." FDA said these are unapproved new drugs and their labeling lacks adequate directions for use, which makes them misbranded.
What FDA found
The company offers botulinum toxin type A as "Nabota 200ui" without any FDA-approved application for it.
Sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d), 355(a)]Website claims that the product treats blepharospasm and hyperhidrosis show it is a drug intended for human use.
21 CFR 201.128; section 201(g) of the FD&C Act [21 U.S.C. § 321(g)]The product's labeling does not give adequate directions for use, which is required for a drug.
Section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]Because it is a prescription drug for conditions a layperson cannot self-treat, safe directions cannot be written for consumers to use it on their own.
Section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]The product is not excused from the adequate-directions requirement because it is not approved in the U.S.
21 CFR 201.115(a)By offering these drugs to U.S. consumers, the website causes misbranded drugs to enter interstate commerce.
Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to stop offering unapproved and misbranded drugs for sale to U.S. consumers and to review its websites, labels, and promotional materials. The company must reply in writing within 15 working days describing the steps taken and providing supporting documents.
Who should pay attention
- U.S. clinics and med spas that buy injectables from overseas suppliers
- distributors and importers of aesthetic injectable drugs
- consumers who buy prescription cosmetic drugs from websites
This is a summary. Read the original letter on fda.gov.